| Ytd | -6.79% | |
| 1y | -32.74% |
| Open | 0.57 | Prev Close | 0.57 | Low | 0.57 | High | 0.59 | Mkt Cap | 14.26M |
| Vol | 14.62K | Avg Vol | 136.46K | EPS | -0.47 | P/E | N/A | Forward P/E | -5.64 |
| Beta | 1.06 | Short Ratio | 2.34 | Inst. Own | 6.08% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-14 | 50-d Avg | 0.65 | 200-d Avg | 0.83 | 1yr Est | 10.00 |
LEXX News
Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innova
Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (t
KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analy
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov
Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and
Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with com
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-sema
Lexaria Bioscience Corp. (NASDAQ:LEXX)(LEXXW) (the "Company" or "Lexaria"), a global
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a
Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 po
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday&#
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Fri
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a glob
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announc
Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a dramatic 45.10% surge in after-hours trading o
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001348362/000164033425001717/lxrp_8k.htm
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyL
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-se
The fastest growing sector in the global pharmaceutical industry is struggling to face its most seri
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the ana
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotineKELOWN
